Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

PF-219,061

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
PF-219,061
Clinical data
Routes of
administration		Nasal
Legal status
Legal status
  • Investigational (discontinued)
Identifiers
  • (R)-3-(4-propylmorpholin-2-yl)phenol
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC13H19NO2
Molar mass221.300 g·mol−1
3D model (JSmol)
  • CCCN1CCO[C@@H](C1)C2=CC(=CC=C2)O
  • InChI=1S/C13H19NO2/c1-2-6-14-7-8-16-13(10-14)11-4-3-5-12(15)9-11/h3-5,9,13,15H,2,6-8,10H2,1H3/t13-/m0/s1 ☒N
  • Key:WYEGTIGJSHGEID-ZDUSSCGKSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

PF-219,061 is a drug that was underdevelopment byPfizer which acts as a potent and highlyselectiveagonist for thedopamineD3receptor.[1][2] It was under development as a potential medication for the treatment offemale sexual dysfunction.[3][4] It did not advance into clinical trials.[5]

See also

[edit]

References

[edit]
  1. ^Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, et al. (December 2007). "Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route".Bioorganic & Medicinal Chemistry Letters.17 (24):6691–6.doi:10.1016/j.bmcl.2007.10.059.PMID 17976986.
  2. ^Brioni JD, Moreland RB (2006). "Dopamine D4 receptors and the regulation of penile erection".Drug Discovery Today: Therapeutic Strategies.3 (4):599–604.doi:10.1016/j.ddstr.2006.10.006.
  3. ^Van Der Graaf et al. Selective Dopamine D3 Receptor Agonists for the Treatment of Sexual Dysfunction, WIPO Patent WO2003051370, granted to Pfizer
  4. ^Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I (July 2009). "Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061".Xenobiotica; the Fate of Foreign Compounds in Biological Systems.39 (7):523–33.doi:10.1080/00498250902893775.PMID 19480558.S2CID 26474660.
  5. ^Cortés A, Moreno E, Rodríguez-Ruiz M, Canela EI, Casadó V (July 2016). "Targeting the dopamine D3 receptor: an overview of drug design strategies".Expert Opinion on Drug Discovery.11 (7):641–64.doi:10.1080/17460441.2016.1185413.PMID 27135354.S2CID 205917989.
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
Retrieved from "https://en.wikipedia.org/w/index.php?title=PF-219,061&oldid=1300551239"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp